Pacira BioSciences' Cost of Revenue fell 1180.01% to $34.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.3 million, marking a year-over-year decrease of 1621.35%. This contributed to the annual value of $170.4 million for FY2024, which is 771.16% down from last year.
Per Pacira BioSciences' latest filing, its Cost of Revenue stood at $34.3 million for Q3 2025, which was down 1180.01% from $40.9 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Cost of Revenue registered a high of $61.9 million during Q4 2022, and its lowest value of $31.3 million during Q1 2021.
In the last 5 years, Pacira BioSciences' Cost of Revenue had a median value of $39.9 million in 2024 and averaged $42.3 million.
Per our database at Business Quant, Pacira BioSciences' Cost of Revenue skyrocketed by 5873.05% in 2022 and then crashed by 2764.89% in 2025.
Pacira BioSciences' Cost of Revenue (Quarter) stood at $39.0 million in 2021, then skyrocketed by 58.73% to $61.9 million in 2022, then dropped by 22.97% to $47.7 million in 2023, then dropped by 16.37% to $39.9 million in 2024, then decreased by 14.06% to $34.3 million in 2025.
Its last three reported values are $34.3 million in Q3 2025, $40.9 million for Q2 2025, and $34.3 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value